Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Jan 12, 2022

SELL
$84.37 - $133.6 $8,437 - $13,360
-100 Closed
0 $0
Q4 2020

Jan 19, 2021

BUY
$22.24 - $95.63 $2,224 - $9,563
100 New
100 $8,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track First Command Financial Services, Inc. Portfolio

Follow First Command Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Command Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Command Financial Services, Inc. with notifications on news.